PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 3557296
• 负责人: V M WHITEHEAD
• 金额: $ 2.7万
• 依托单位: MONTREAL CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-01-01 至 1985-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557296
• 关键词: cancer registry /resource; cooperative study; cytogenetics; drug adverse effect; drug metabolism; folate; human subject; human therapy evaluation; lymphoma; lymphosarcoma; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer surgery; neuroblastoma; pediatric neoplasm /cancer; vitamin B12

Support is requested for participation in all clinical and laboratory investigative activities of the Pediatric Oncology Group (POG). The POG is a new pediatric cooperative group comprising the pediatric components of the SWOG and the CALGB, with the addition of several new institutions. Specifically, these funds will assist our efforts in cooperative cancer therapy trials which utilize a combination of surgery and/or radiation therapy and/or chemotherapy for the treatment of leukemias, lymphomas, solid tumors and brain tumors. Emphasis will be placed on integrated multimodality treatment programs in phase III randomized prospective studies. We shall also participate in pilot and group wide phase II studies of new chemotherapeutic agents. Support will permit us to enter the maximum number of patients on study and ensure complete documentation of patient data: will permit members to attend Pediatric Oncology Group meetings and to participate in working sub-committees, protocol planning committees and study writing committees; and will permit group wide studies of methotrexate pharmcology to be carried out.

请为参加所有临床和实验室活动提供支持 儿童肿瘤学小组(POG)的调查活动。POG是 一个新的儿科合作小组，由以下儿科组成部分组成 SWOG和CALGB，增加了几个新的机构。 具体地说，这些资金将帮助我们在癌症合作方面的努力。 结合手术和/或放射治疗的治疗试验 治疗和/或化疗白血病、淋巴瘤、 实体瘤和脑瘤。重点将放在综合 第三阶段随机前瞻性的多模式治疗方案 学习。我们还将参与试点和集团范围的第二阶段 新型化疗药物的研究。支持人员将允许我们进入 研究中患者的最大数量，并确保完整的文档 患者数据：将允许成员参加儿科肿瘤学小组 参加会议并参加工作小组委员会、礼宾规划 委员会和研究写作委员会；并将允许小组范围内的研究 将进行的甲氨蝶呤药理学研究。